Rigor Reviewed

Rigor-Reviewed Manuscript

Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria.

Name: Αlpha¹ Rigor Record — Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria.
Item: Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria.
Rating: 96
Author: Αlpha¹

Kayentao K, Ongoiba A, Preston AC, Healy SA, Hu Z, Skinner J, Doumbo S, Wang J, Cisse H, Doumtabe D, Traore A, Traore H, Djiguiba A, Li S, Peterson ME, Telscher S, Idris AH, Adams WC, McDermott AB, Narpala S, Lin BC, Serebryannyy L, Hickman SP, McDougal AJ, Vazquez S, Reiber M, Stein JA, Gall JG, Carlton K, Schwabl P, Traore S, Keita M, Zéguimé A, Ouattara A, Doucoure M, Dolo A, Murphy SC, Neafsey DE, Portugal S, Djimdé A, Traore B, Seder RA, Crompton PD, Mali Malaria mAb Trial Team

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.75★ (Adequate), 0 critical, 3 high issues for “Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.75 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No reported statistical tests were found to recompute.

Problems surfaced3 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted phase 2 randomized, double-blind, placebo-controlled trial with rigorous design, clear ethical approvals, and appropriate statistical methods. The main weaknesses are minor reporting gaps: a vague data sharing statement, no explicit power analysis, no named statistical software, and no explicit reporting guideline adherence.

Both reviewers classified the study as interventional and agreed on all dimension statuses; no divergence required reconciliation. The statistics verification component covered only a subset of tests (none recomputed due to threshold-only p-values), so the statistical analysis is not fully machine-verified; the citation check found no retracted or unresolved references.

5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites the high malaria mortality, limitations of current vaccines and chemoprevention, and prior phase 1/2 trials of CIS43LS and L9LS, providing a strong rationale for testing L9LS in children. The limitations of prior work (e.g., need for repeated dosing, coverage challenges) are acknowledged, and the study directly addresses the gap of subcutaneous administration in children in an endemic area.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior work on malaria burden, existing vaccines, and prior monoclonal antibody trials, and logically motivates the need for a new intervention.

Evidence

paraphrase[Introduction, paragraph 1]

“PLASMODIUM FALCIPARUM causes more than 600,000 deaths from malaria annually, mostly among children in Africa.”

paraphrase[Introduction, paragraph 3]

“In a phase 2 trial involving adults in Mali, an intravenous infusion of CIS43LS... provided protective efficacy against P. falciparum infection of 75.0% and 88.2%...”

direct quote[Introduction, paragraph 3]

“Here, we report the results of a phase 2 trial that was conducted in Mali to assess the safety and efficacy of subcutaneous administration of L9LS against P. falciparum infection in healthy children 6 to 10 years of age over the 6-month malaria season.”